Core Viewpoint - Hema Medical (03309) experienced a significant stock price increase of over 8%, reaching HKD 2.09, following the announcement of a global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. for the antiviral drug encequidar [1] Group 1: Company Developments - Hema Medical's subsidiary entered into a tripartite global licensing and collaboration agreement regarding the first P-glycoprotein inhibitor in the virology field [1] - The agreement grants Gilead exclusive global rights to encequidar, while Hema Medical and Hanmi will provide drug supply and share technical knowledge [1] - Hema Medical is set to receive an upfront payment of USD 10 million upon meeting certain conditions and milestones during the agreement period, with potential future payments reaching up to approximately USD 72.5 million [1] Group 2: Financial Implications - Hema Medical will also have the right to receive royalties at a low single-digit percentage on net sales of the drug [1]
港股异动 | 希玛医疗(03309)高开逾8% 希华医药订立授权及合作协议 将获千万美元首付款